Stoke Therapeutics, Inc. Profile Avatar - Palmy Investing

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Aug…

Biotechnology
US, Bedford [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Stoke Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of STOK's Analysis
CIK: 1623526 CUSIP: 86150R107 ISIN: US86150R1077 LEI: - UEI: -
Secondary Listings
STOK has no secondary listings inside our databases.